Review of the Long-Term Implantable Senseonics Continuous Glucose Monitoring System and Other Continuous Glucose Monitoring Systems
- 29 April 2020
- journal article
- review article
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 15 (1) , 167-173
Abstract
The article published by Kevin Cowart in this issue of the Journal of Diabetes Science and Technology (JDST) is a detailed overview of the clinical trial data and analysis used to demonstrate the safety and effectiveness of the Eversense continuous glucose monitoring (CGM) System for regulatory approval and clinical acceptance. The article describes the published study results for safety, accuracy, reliability, ease of insertion/removal, adverse events, and ease of diabetes patient-use for controlling their glucose levels short and long term. The author nicely compares Eversense CGM System safety and performance with the short-term subcutaneous tissue CGM systems being commercialized by Dexcom, Medtronic Diabetes, and Abbott Diabetes. This comparison may help the clinician define which type of patient with diabetes might benefit the most from the long-term implantable CGM system. The majority of studied patients describe a positive experience managing their diabetes with the Eversense CGM System and request implantation of a new sensor 90 or 180 days later.Keywords
This publication has 72 references indexed in Scilit:
- Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 DiabetesDiabetes Care, 2011
- Function of an Implanted Tissue Glucose Sensor for More than 1 Year in AnimalsScience Translational Medicine, 2010
- A Bihormonal Closed-Loop Artificial Pancreas for Type 1 DiabetesScience Translational Medicine, 2010
- Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial PancreasDiabetes Care, 2008
- Foreign body reaction to biomaterialsSeminars in Immunology, 2008
- Study of the effects of tissue reactions on the function of implanted glucose sensorsJournal of Biomedical Materials Research Part A, 2007
- Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) TrialThe American Journal of Cardiology, 2007
- The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysisDiabetologia, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The physiology of wound healingAnnals of Emergency Medicine, 1988